



GILEAD

Advancing Therapeutics.
Improving Lives.



GILEAD SCIENCES
RESEARCH
SCHOLARS
PROGRAM IN **HIV**

*Supporting innovative
scientific research
that will advance
knowledge in the
field of HIV*

<http://researchscholars.gilead.com>



GILEAD SCIENCES
RESEARCH
SCHOLARS
PROGRAM IN **HIV**

TABLE OF CONTENTS

Mission Statement.....	2
Program Overview.....	2
Scientific Focus	2
Scientific Review Committee.....	3
Eligibility	3
Criteria for Selection.....	4
Application Information.....	5
Guidelines for the Research Proposal.....	6
Budget Guidelines.....	6
Program Timeline.....	7
Inquiries/Contact Information.....	7
Funding Considerations.....	7
Previous Award Recipients.....	9

MISSION STATEMENT

The mission of the Gilead Sciences Research Scholars Program in HIV (the “program”) is to support innovative scientific research that will advance knowledge in the field of HIV and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of HIV.

PROGRAM OVERVIEW

The program provides financial support to the institutions of 4 junior faculty researchers for a 2-year period. Each award is funded up to USD130,000 (inclusive of any indirect costs), to be paid in annual installments of up to USD65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report by each junior faculty researcher and approval by the Co-Chairs of the Scientific Review Committee which oversees the program.

Recipients of these competitive awards under the program will be selected by a Committee (as defined below) comprised of leaders in the field of HIV (the “Scientific Review Committee” or the “Committee”). The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, and innovation. Announcement of Award Recipients will be made at an awards dinner hosted by the Committee and senior representatives from Gilead.

Applicants must meet the eligibility criteria in order to be considered for an award. Refer to the **Eligibility** section on page 3.

SCIENTIFIC FOCUS

The program is designed to support basic and clinical research in the field of HIV. Areas of research may include, but are not limited to:

- HIV treatment and management
- HIV and its complications in special populations (aging, women, people of color, etc)
- HIV prevention
- Basic, clinical, and translational research related to HIV
- Health economics outcomes research relating to HIV

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Proposals are reviewed by an independent Scientific Review Committee (no Commercial involvement in review and selection, ie, Marketing, Sales and Commercial Strategy), and are reviewed based upon the criteria outlined in this brochure.

SCIENTIFIC REVIEW COMMITTEE

Applications will be reviewed by the Committee, comprised of internationally recognized experts in basic and clinical research in the field of HIV.

Co-Chairs:

Alan L. Landay, PhD

Professor of Departments of
Internal Medicine and Microbial
Pathogens and Immunity
Rush University Medical Center
Chicago, IL

Paul Sax, MD

Professor of Medicine Harvard
Medical School Clinical Director,
Division of Infectious Diseases
Brigham and Women's Hospital
Boston, MA

Review Committee:

Eric S. Daar, MD

Interim Chair, Department of Medicine
Chief, Division of HIV Medicine Harbor-
UCLA Medical Center Professor of
Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Eric Hunter, PhD

Professor, Pathology and
Laboratory Medicine
Emory University
School of Medicine
Atlanta, GA

Christine Durand, MD

Assistant Professor
Division of Infectious Diseases
Johns Hopkins University
School of Medicine
Baltimore, MD

Athe Tsibris, MD, MS

Assistant Professor
Harvard Medical School Brigham
and Women's Hospital
Boston, MA

David Alain Wohl, MD

Professor, Division of Infectious Diseases
Site Leader, UNC AIDS Trials Unit at Chapel Hill
The University of North Carolina at Chapel Hill
Chapel Hill, NC

ELIGIBILITY

This award is intended for junior faculty who meet the criteria for Early Stage Investigator, as defined by the National Institutes of Health (NIH) (<https://grants.nih.gov/policy/early-investigators/index.htm>). Note, those who have received substantial NIH research awards, such as being a PI on an R01, P01, or U01, are not Early Stage Investigators, according to the NIH criteria. A list of NIH grants that a PI can hold and still be considered an Early Stage Investigator can be found at: <https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm>.

In addition, applicants must meet the following requirements:

- Hold an MD, DO, PhD, or equivalent degree at time of award
- Be within 5 years of a faculty appointment in association with a research institution in Canada or the United States at the time of application

- Have a strong career interest in HIV
- Have a research mentor with extensive experience in the field of HIV
- Be able to devote at least 50% of professional time to research (versus administrative, patient care, or teaching responsibilities)
- Be able to complete the proposed research within the 2-year award period, providing evidence (manuscript, presentation, or abstracts) for future research projects.

Citizenship

An applicant must be a citizen or permanent resident of Canada or the United States or hold a temporary nonimmigrant visa. This visa must be valid for the two-year award period (June 1, 2019 – May 31, 2021).

CRITERIA FOR SELECTION

In their evaluation, the Committee will consider the following criteria:

Criterion 1: Evaluation of the Applicant

- Potential for a career in HIV-related research
- Academic record
- Prior research experience and/or publications

Criterion 2: Scientific Environment and Institutional Support

- Letter of support from mentor which includes: mentor's track record of productivity, funding, and success with prior trainees; detailed description of the mentoring plan, including resources allocated to the proposed research project, provision of protected time, and available laboratory facilities.
- The mentor is an independent investigator.
- The mentor has the experience to direct the proposed research training, as evidenced by the letter of support.
- The training plan is sufficient to facilitate the applicant's progress toward his/her research career goals.
- The proposed scientific environment contributes to the probability of success for the training experience.
- Letter of support from the department chair or division chief to document the institution is willing and has the ability to commit the resources necessary for the applicant to complete the proposed research, including sufficient protected time.

Criterion 3: Evaluation of the Proposal

- *Innovation and Significance:* The research proposal is new and original and addresses an important question/issue related to HIV. The proposed study will have an effect on concepts, methods, and/or technologies related to HIV research.
- *Approach:* The conceptual framework, design, methods, and analyses are adequately developed, well-integrated, well-reasoned, feasible (as determined

by preliminary data or the expertise available), and appropriate to the aims of the project. The applicant acknowledges potential problem areas and considers alternative tactics.

- **Feasibility:** The project, as described in the submitted proposal and budget, can be accomplished within the time frame of the award.

APPLICATION INFORMATION

Submission Deadline: Monday, January 14, 2019, 11:59 PM, Pacific Standard Time. No applications will be accepted after this date.

Applications must be completed online and submitted electronically with the required Supplementary Materials to <http://researchscholars.gilead.com>
If you have any questions, or require further information, please contact:

Gilead Sciences Research Scholars Program in HIV

Attn: Research Scholars Program Coordinator

Telephone: 919 534-7653

E-mail: gileadsciences@bcdme.com

Application

Applicants must complete the online Application Form (all fields must be completed or applicant will not be able to submit) and include the following Supplementary Materials as specified:

- Research Abstract
- Research Proposal
- Applicant's NIH biosketch, inclusive of publications, if applicable
- Mentor's biosketch
- Letter of support from mentor which includes: mentor's track record of productivity, funding, and success with prior trainees; detailed description of the mentoring plan, including resources allocated to the proposed research project, provision of protected time and available laboratory facilities
- Bibliography of relevant references (maximum of 20)
- Detailed budget and completed budget summary
- Acknowledgement of Indirect Costs Limitation, using the template provided on the program website
- Certification of Faculty Appointment from mentor is required and must be submitted with the application, using the template provided on the program website
- Current or Pending Funding, using the template provided on the program website
- Letter of support from the department chair or division chief that documents the institution is willing and has the ability to commit the resources necessary for the applicant to complete the proposed research, including sufficient protected time

GUIDELINES FOR THE RESEARCH PROPOSAL

The Research Proposal should be a clear and concise presentation of the applicant's proposed research.

The Proposal must include:

Research Abstract

Provide an abstract of no more than 325 words outlining the applicant's proposed research.

Research Proposal

Proposal must be single-spaced (using 11 point Arial font or larger) and limited to 5 pages total, not including the bibliography or budget. Research proposals over 5 pages will not be accepted. Please include your bibliography with the research proposal but do not count these pages in the 5 page total.

The proposal must include:

1. Title of the proposed research
2. Description of research objectives, including relevant literature, specific aims, study design, methodology, data, and projected results
3. Discussion of the relevance of the proposed research to the objectives of the program (see **Scientific Focus** on page 2)
4. Description of analytical methods (figures and tables should be included in the body of the text, where applicable)
5. Description of potential research challenges and possible approaches for overcoming them
6. Description of relevant past work by the applicant, including joint collaborations and references

BUDGET GUIDELINES

Indirect Costs:

- In an effort to maximize the research benefit of the award, the program encourages that every effort be made to minimize the utilization of the award to cover indirect costs. Indirect costs may not exceed 10% of the award value. This award is developed as a gift and is not considered a research grant.

Salaries:

- The applicant may allocate up to USD50,000 per year in salary and fringe benefits support for the applicant and/or a technician.
- Salaries and fringe benefits for mentors, post-doctoral fellows, or students may not be included.

Supplies:

- Supplies such as disposables, chemicals, reagent kits, animals, etc, may be included
- Equipment purchases with a single item value of greater than USD2,500 may not be included

Travel:

- Up to USD1,500 per year for applicant's travel to a scientific meeting for presentation of data may be included

If the research project includes investigations on human subjects, a copy of the submission to the institutional review board (IRB) must be submitted prior to award. Award will be contingent upon IRB approval.

If the research project involves laboratory animals, researcher must certify that he/she will comply with all laws and regulations pertaining to care and use of animals in research prior to award.

PROGRAM TIMELINE

The timeline, from application submission to award disbursement, is below:

Application Deadline	January 14, 2019
Applicant Notification	April 15, 2019
Award Disbursement	June 1, 2019

INQUIRIES/CONTACT INFORMATION

For general inquiries about the Research Scholars Program, please call or e-mail:

Gilead Sciences Research Scholars Program in HIV

Attn: Research Scholars Program Coordinator

Telephone: 919 534-7653

E-mail: gileadsciences@bcdme.com

If you experience technical difficulties when registering on the website or submitting an application, please contact HDMZ Client Services at 800-523-2392 or email webmaster@hdmz.com

FUNDING CONSIDERATIONS

If you are selected as an award recipient, you and your institution must agree to the following items, including, but not limited to:

■ Exclusive Use of Funding

In an effort to maximize the research benefit of the award, the program encourages that every effort be made to minimize the utilization of the award to cover indirect costs. Indirect costs may not exceed 10% of the award value. Funding is contingent upon Committee approval of the itemized budget. This award is developed as a gift and is not considered a research grant.

■ Use of Gilead Product

Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through our online portal: <http://www.gilead.com/research/investigator-sponsored>

■ Progress Reports

Submission of research progress and financial accounting reports for review by the Committee are required annually. Funding for the second year is contingent upon Committee Chair approval of the research progress report.

■ Publications

The support received under the program must be acknowledged in any publication or abstracts resulting from research funded by this award.

■ Intellectual Property

The host institution shall retain ownership of any invention conceived and reduced to practice during the length of the award resulting solely from the Research Plan. The invention shall be Confidential Information of the institution.

■ Change of Award Recipient, Institution, or Discontinuation

The Research Scholars Program Coordinator must be notified immediately if the award recipient leaves the host institution or discontinues the research funded by the program. In the event award recipient moves to another institution, the award may be transferred or suspended at the sole discretion of the Committee. The new host institution must also agree to accept the terms and conditions of the existing award. In the event the host institution or award recipient is unable to complete the research or desires to discontinue the research before its completion, institution will be required to return all unexpended funds and any remaining award will be terminated.

Award recipients and their institutions will be required to enter into a written grant agreement with Gilead Sciences, Inc. prior to receipt of funding.

PREVIOUS AWARD RECIPIENTS

2018 Recipients

Lalit Deshmukh, PhD

University of California San Diego

"Targeting the transient dark state of HIV-1 nucleocapsid with small drug-like molecules"

Ya-Chi Ho, MD, PhD

Yale University School of Medicine

"Single-cell characterization of HIV-1-infected cells."

Ellen Eaton, MD, MSPH

University of Alabama, Birmingham

"Improving Kidney Health for African Americans with HIV through Optimal Antiretroviral Therapy Selection"

Suzanne McCluskey, MD

Massachusetts General Hospital

"Appraising World Health Organization Recommendations to Switch Nucleos(t)ide Reverse Transcriptase Inhibitor At First-Line Virologic Failure."

2017 Recipients

Stylianos Bournazos, PhD

The Rockefeller University

"Development and Evaluation of Anti-HIV-1 Antibodies with Potent Cytotoxic Activity Against HIV-1 Infected Cells"

Jennifer A Downs, MD, PhD

Weill Cornell Medicine

"Mechanisms of Mucosal HIV Susceptibility and Reversibility in Schistosoma mansoni Infection"

Catherine A. Koss, MD

University of California, San Francisco

"Development of a Social Network-Enhanced Adherence Intervention for PrEP in Young African Women"

Raeanne C. Moore, PhD

HIV Neurobehavioral Research Program (HNRP)

at the University of California, San Diego (UCSD)

"Remote Sensing Technology to Improve Community-Based Fall Risk Assessment and Prevention Among Older Adults Living with HIV"

PREVIOUS AWARD RECIPIENTS

2015 Recipients

Kristine M. Erlandson, MD

University of Colorado

"Moderate- or High-Dose Exercise to Attenuate Inflammation in HIV and Aging"

Jonathan Z. Li, MD

Brigham and Women's Hospital, Harvard Medical School

"Discovery of Monoclonal Therapeutics for Long-Term HIV Control"

Daniel Lingwood, PhD

The Ragon Institute of MGH, MIT, and Harvard

*"IGHV1-2*02 Antibody Expansion as a Genetic Template for an HIV Vaccine"*

Jennifer Price, MD

University of California, San Francisco

*"The Influence of HIV Infection on the Natural History of
Nonalcoholic Fatty Liver Disease"*

*Supporting innovative scientific research
that will advance knowledge
in the field of HIV*



© 2018 Gilead Sciences, Inc. All rights reserved. GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc.